Subcutaneous vs. IM Testosterone: what the PK data shows

Subcutaneous testosterone injections produce steadier serum levels than intramuscular injections, with lower peaks and similar troughs at the same weekly dose. The smoother curve is linked to less pain, easier self-administration, and reduced side effects like mood swings and water retention.

If you've been on TRT for more than about ten minutes, someone has told you that intramuscular injections are the "real" way to do it and subcutaneous shots are for beginners. The pharmacokinetic literature does not agree.

Over the last decade, several head-to-head studies have measured serum testosterone, estradiol, hematocrit, and patient-reported outcomes across both routes. The pattern is consistent: subcutaneous injection of testosterone cypionate or enanthate produces slightly lower peaks, similar troughs, and a smoother curve than the same dose given intramuscularly. For most patients, that translates to fewer symptoms of the peak-and-crash cycle — mood swings, water retention, and estradiol spikes.

Here's what the data actually says, and how to think about picking a route.

Why the injection route matters at all

Testosterone cypionate and enanthate are esterified compounds suspended in oil. Once injected, the oil depot slowly releases testosterone into circulation. The rate of that release depends on where the depot sits — and how well the surrounding tissue is perfused.

Skeletal muscle has high blood flow. Subcutaneous fat has less. That single fact is why the curves look different.

• Intramuscular (IM): faster absorption, higher peak (Cmax), shorter time-to-peak (Tmax).
• Subcutaneous (subQ): slower absorption, flatter peak, longer effective release window.

Both routes deliver the same total testosterone into your system over the dosing interval (the AUC, or area under the curve, is comparable in most studies). The difference is how that testosterone shows up — a slow drip versus a wave.

What the head-to-head studies show

The cleanest data comes from a handful of prospective trials and pharmacokinetic analyses:

• Kaminetsky et al. (2019), published in Journal of Sexual Medicine, followed men on weekly subcutaneous testosterone enanthate for 12 weeks. Total testosterone stayed in the mid-normal range with minimal peak-trough variability, and no injection-site reactions required discontinuation.
• Turner et al. (2019), in Andrology, compared subQ and IM testosterone cypionate. Peak levels were roughly 15–20% lower on subQ at the same dose, but trough levels were nearly identical.
• Spratt et al. (2017), in the Journal of Clinical Endocrinology & Metabolism, showed that low-volume subcutaneous testosterone produced stable eugonadal levels in transgender men and hypogonadal cisgender men alike, with fewer supraphysiologic spikes.

The takeaway across studies: at the same weekly dose, subQ gets you to the same average testosterone with a gentler curve.

If your goal is stable serum levels and fewer estradiol swings, the PK data favors subcutaneous dosing at the same total weekly amount.

What about estradiol and hematocrit?

This is where the smoother curve starts to matter clinically.

Aromatase — the enzyme that converts testosterone to estradiol — works faster when substrate is abundant. A big IM peak means a bigger, briefer estradiol surge. Several observational reports and smaller trials suggest subQ dosing produces lower peak estradiol at equivalent testosterone exposure, though the effect is modest and not universal.

Hematocrit is similar. Erythrocytosis (hematocrit creeping above 52–54%) is one of the most common reasons TRT gets paused or dose-reduced. Peak testosterone appears to drive erythropoiesis more than average testosterone does. In practice, clinicians who switch patients from once-weekly IM to twice-weekly subQ often see hematocrit trend down over 3–6 months at the same total dose.

That's not a guarantee — genetics, sleep apnea, hydration, and baseline red cell mass all matter — but the mechanism is coherent with the PK data.

The clinical bottom lineAt the same weekly dose, subcutaneous testosterone typically produces a flatter curve, lower peak estradiol, and often lower hematocrit than intramuscular — with equivalent trough levels and symptom control.

Does subQ actually work as well symptomatically?

Yes, in the trials that measured it. Kaminetsky's cohort reported improvements in energy, libido, and mood consistent with what you'd expect from IM TRT at similar serum levels. Patient satisfaction scores actually favored subQ, largely because of two things:

1. Less pain. A 27–30 gauge insulin syringe into the abdomen or thigh hurts less than a 23–25 gauge intramuscular shot into the glute or quad. 2. Easier self-administration. No hunting for the ventrogluteal landmark. No 1.5-inch needle. Most patients can self-inject subQ in under a minute after a week of practice.

There's also less bruising, fewer post-injection flares, and — for men who inject twice weekly — a meaningful reduction in the psychological friction of dosing day.

When IM still makes sense

SubQ is not universally better. A few scenarios where IM remains the right call:

• Very lean patients with minimal subcutaneous fat. If you can't pinch a comfortable inch of tissue, subQ isn't practical and absorption gets erratic.
• High-dose protocols. Volumes above ~0.5 mL per subQ injection can cause local nodules or discomfort. Splitting into more frequent doses helps, but some patients prefer a single IM shot.
• Persistent injection-site reactions to subQ. A small subset of men develop itchy red welts at subQ sites — sometimes from the carrier oil (cottonseed vs. grapeseed vs. sesame), sometimes from the ester itself. Rotating to IM often resolves it.
• Patient preference. Some men simply feel better on the IM curve. That's a legitimate reason to stay on it.

Dosing frequency matters more than route

Here's the part that gets lost in the subQ-vs-IM debate: frequency flattens the curve more than route does.

A once-weekly IM injection produces a much larger peak-to-trough swing than a twice-weekly subQ injection at the same total dose — but a twice-weekly IM protocol is also much smoother than once-weekly IM. Splitting the dose is doing most of the work.

Standard published titration ranges for testosterone cypionate/enanthate in men typically fall between 100–200 mg per week total, divided into one, two, or occasionally three injections depending on symptoms, labs, and side effect profile. Your clinician should be picking frequency based on your trough level, your peak estradiol, and how you actually feel — not tradition.

What labs are worth tracking

Route and frequency decisions get a lot easier when you have real numbers. The labs worth having before or during a serious TRT protocol usually include:

• Total and free testosterone (drawn at trough — right before your next injection — to interpret cleanly)
• Estradiol, ideally by LC-MS/MS (sensitive assay), not the older immunoassay
• CBC with hematocrit and hemoglobin
• SHBG, which changes how you interpret total T
• PSA at baseline and periodically after age 40
• Lipid panel and metabolic markers if you have cardiovascular risk factors

A thorough workup would typically include these markers before dialing in dose and frequency, and again 8–12 weeks after any change. If you choose to run bloodwork through us, these are the markers we look at first when deciding whether subQ or IM — and how often — is the right fit.

The practical answer

If you're starting TRT and you don't have a strong reason to prefer IM, subcutaneous injection twice weekly is a reasonable default supported by the pharmacokinetic literature. It's gentler, easier, and produces the steady serum levels most men are chasing when they start therapy in the first place.

If you're already on IM and doing well — same total testosterone, tolerable estradiol, hematocrit under 52%, symptoms controlled — there's no urgent reason to switch. The route that works for your body and your schedule is the right route.

What matters is that the decision is made with real data: your trough levels, your estradiol, your hematocrit, and how you actually feel between injections. Not internet dogma about which needle is more legitimate.

References

1. Wilson DM et al. Pharmacokinetics, safety, and patient acceptability of subcutaneous versus intramuscular testosterone injection for gender-affirming therapy: A pilot study. Am J Health Syst Pharm. 2018. Source
2. Kaminetsky J et al. Pharmacokinetic Profile of Subcutaneous Testosterone Enanthate Delivered via a Novel, Prefilled Single-Use Autoinjector: A Phase II Study. Sex Med. 2015. Source

Editorial disclosure: This article is for informational purposes only and does not constitute medical advice. All treatments at DirectCare AI are prescribed by US-licensed clinicians based on individual medical evaluation. Compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality. Always consult a US-licensed clinician before starting or changing any therapy.